International Journal of Cardiology. Cardiovascular Risk and Prevention · Published 2026-07-22 · DOI 10.1016/j.ijcrp.2026.200686
M. Ali, S.H. Sheikh Abdul Kadir, E. Ibrahim, Abdulaziz Albaraikan
Background and rationale: Tocotrienol-rich fraction (TRF), a naturally occurring mixture of four tocotrienol isoforms (α-, β-, γ-, and δ-tocotrienol) derived principally from palm oil, constitutes a structurally and functionally distinct sub-family of vitamin E with demonstrably superior biological activity compared with α-tocopherol. Diabetes mellitus (DM) and its principal macrovascular complication, cardiovascular disease (CVD), remain the leading drivers of global morbidity and mortality, with an estimated 529 million adults currently affected and projections exceeding 1.3 billion by 2050. The shared pathological substrate of diabetic CVD—comprising reactive oxygen species (ROS)-mediated oxidative stress, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-driven chronic inflammation, insulin resistance, dyslipidaemia, and endothelial dysfunction represents a multi-target landscape ideally suited to TRF's pleiotropic pharmacology. Objective: This narrative review synthesises the molecular mechanisms, preclinical evidence, and available clinical data underpinning TRF as a nutraceutical intervention for diabetes-associated CVD, and identifies critical gaps requiring further investigation. Key findings: TRF exerts cardioprotection through five mechanistically distinct axes: (i) direct scavenging of ROS and inhibition of lipid peroxidation via superior membrane integration conferred by its unsaturated isoprenoid side chain; (ii) suppression of NF-κB signalling and downstream pro-inflammatory mediators including tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β); (iii) HMG-CoA reductase inhibition with consequent reductions in low-density lipoprotein (LDL) cholesterol and triglycerides; (iv) restoration of nitric oxide (NO) bioavailability and attenuation of vascular adhesion molecules (intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1]); and (v) peroxisome proliferator-activated receptor-gamma (PPAR-γ) and PPAR-α agonism, enhancing insulin sensitivity and fatty acid oxidation. Clinical meta-analysis confirms significant glycated haemoglobin (HbA1c) reduction (standardised mean difference [SMD] −0.44; 95% confidence interval [CI] −0.82 to −0.02; p = 0.03) and consistent lipid-profile improvements at doses of 200–420 mg/day in type 2 diabetes mellitus (T2DM) patients. Conclusion: TRF occupies a unique mechanistic niche among nutraceuticals by simultaneously addressing all five core pathological drivers of diabetic CVD. Current clinical evidence supports its role as a meaningful glycaemic and cardioprotective adjunct. Adequately powered randomised controlled trials (RCTs) with primary cardiovascular endpoints, standardised formulations, and combination strategies with established antidiabetic agents are required to translate TRF into evidence-based clinical practice.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Ali, M., Kadir, S., Ibrahim, E., et al. (2026). Tocotrienol-rich fraction of vitamin E in diabetes and cardiovascular disease: From molecular mechanisms to clinical application. International Journal of Cardiology. Cardiovascular Risk and Prevention. https://doi.org/10.1016/j.ijcrp.2026.200686